The number of planned and ongoing clinical trials (new) for medical devices in Q4 2021 saw a decrease 17% globally when compared with the last four–quarters average, according to GlobalData’s medical devices clinical trials database.

The global medical devices market was worth $479.97bn in 2020 and is expected to reach $532.37bn by 2023, according to GlobalData’s analysis.

Medical devices clinical trials by market: Cardiovascular Devices has the most studies

Looking at the new studies by the type of markets, Cardiovascular Devices accounted for the largest proportion (16%) in Q4 2021, followed by Healthcare IT (14%) and In Vitro Diagnostics (9%).

As for the global medical devices market value, the Cardiovascular Devices market held an 8% share worth $39bn in 2020 and is expected to reach $57.09bn by 2023.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

North America tops new clinical trials activity

Comparing the activity in new clinical trials for medical devices in different regions of the globe, North America held the top position with a 47% share during Q4 2021, followed by Europe with 32%, and Asia-Pacific with 13%.

At the country level, the US had the largest share (42%) of the global medical device clinical trials during the month. In second place was France with a share of 6%, followed by Germany with 6%.

Looking at the share of activity among new clinical trials sponsorship, company-sponsored trials accounted for a 53% share medical devices market, while institute-sponsored trials held the remaining share.

The quarterly average for the last four quarters saw company-sponsored new trials accounting for 52% of new trials and institute-sponsored trials accounting for 48%.

Methodology
The clinical trials data used for the analysis were extracted from the medical Clinical Trials Database of GlobalData’s Medical Intelligence Center. Medical device clinical trials database covers all clinical trials conducted on medical devices, combination devices, diagnostics, and diagnostic imaging agents covering 16 markets (as per medical device taxonomy). GlobalData tracks clinical trials from six key registries: NCT, UMIN, ACTRN, ChiCTR, EudraCT, and ISRCT. It also monitors universities, company websites, press releases, investor presentations and annual reports to track medical device clinical trials. Industry refers to commercial entities such as private and public companies and their subsidiaries. Non-Industry refers to non-profit making entities including hospitals, universities, government research institutions and non-government research institutions. The information is collected by following systematic research techniques and proprietary methodology. Only planned and ongoing clinical trials are considered for this analysis.